Kinases, Homology Models, and High Throughput Docking

Journal of Medicinal Chemistry

Volumn 46, Issue 22, 2003, Pages 4638-4647

  Diller, David J ^a   Li, Rixin ^a  

^a PHARMACOPEIA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1 BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR BLOCKING AGENT; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1 BLOCKING AGENT;

ARTICLE; CRYSTALLOGRAPHY; DRUG DESIGN; ENZYME INHIBITION; GENE SEQUENCE; GENOME; MOLECULAR MODEL; PROTEIN DATABASE; PROTEIN ENGINEERING; PROTEIN FAMILY; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; MODELS, MOLECULAR; PHOSPHOTRANSFERASES; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; SEQUENCE ALIGNMENT;

EID: 0142028937     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020503a     Document Type: Article

References (76)

1. Vitola, J.; Vukanovic, J.; Roden, D. M. Cisapride-induced torsades de pointes. J. Cardiovasc. Electrophysiol. 1998, 9, 1109-1113.
2. Rampe, D.; Roy, M. L.; Dennis, A.; Brown, A. M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 1997, 417, 28-32.
3. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signaling. Nature 2001, 411, 355-365.
4. Kirschenbaum, F.; Hsu, S. C.; Cordell, B.; McCarthy, J. V. Glycogen synthase kinase-3beta regulates presenilin I C-terminal fragment levels. J. Biol. Chem. 2001, 276, 30701-30707.
5. Sanchez, R.; Sali, A. Comparative protein structure modeling. Introduction and practical examples with modeller. Methods Mol. Biol. 2000, 143, 97-129.
6. Zheng, W. H.; Kar, S.; Dor, S.; Quirion, R. Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway. J. Neural Transm. Suppl. 2000, 261-272.
7. Winder, W. W. AMP-activated protein kinase: possible target for treatment of type 2 diabetes. Diabetes Technol. Ther. 2000, 441-448.
8. Wagman, A. S.; Nuss, J. M. Current therapies and emerging targets for the treatment of diabetes. Curr. Pharm. Des. 2001, 7, 417-450.
9. Lee, J. C.; Kumar, S.; Griswold, D. E.; Underwood, D. C.; Votta, B. J.; Adams, J. L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000, 47, 185-201.
10. Goepfert, T. M.; Brinkley, B. R. The centrosome-associated Aurora/Ipl-like kinase family. Curr. Top Dev. Biol. 2000, 49, 331-342.
11. Druker, B. J.; Sawyers, C. L.; Capdeville, R.; Ford, J. M.; Baccarani, M.; Goldman, J. M. Chronic myelogenous leukemia. Hematology 2001, 87-112.
12. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
13. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
14. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999, 6, 775-805.
15. Diller, D. J.; Merz, K. M. High Throughput Docking for Library Design and Library Prioritization. Proteins: Struct. Funct. Genet. 2001, 43, 113-124.
16. Sali, A.; Overington, J. P. Derivation of rules for comparative protein modeling from a database of protein structure alignments. Protein Sci. 1994, 3, 1582-1596.
17. Sali, A.; Potterton, L.; Yuan, F.; van Vlijmen, H.; Karplus, M. Evaluation of comparative protein modeling by MODELLER. Proteins 1995, 23, 318-326.
18. Insight2000; Accelrys, Inc.: San Diego, CA.
19. Catalyst4.5; Accelrys Inc.: San Diego, CA.
20. Gehlhaar, D. K.; Verkhivker, G. M.; Rejto, P. A.; Sherman, C. J.; Fogel, D. B.; Fogel, L. J.; Freer, S. T. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem., Biol. 1995, 2, 317-324.
21. Cerius2; Accelrys, Inc.: San Diego, CA.
22. Boehm, J. C.; Smietana, J. M.; Sorenson, M. E.; Garigipati, R. S.; Gallagher, T. F.; Sheldrake, P. L.; Bradbeer, J.; Badger, A. M.; Laydon, J. T.; Lee, J. C.; Hillegass, L. M.; Griswold, D. E.; Breton, J. J.; Chabot-Fletcher, M. C.; Adams, J. L. 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem. 1996, 39, 3929-3937.
23. Bold, G.; Altmann, K.-H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P. ; Wietfeld, B.; Brueggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Roesel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Laesser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
24. Boschelli, D. H.; Wu, Z.; Klutchko, S. R.; Showalter, H. D.; Hamby, J. M.; Lu, G. H.; Major, T. C.; Dahring, T. K.; Batley, B.; Panek, R. L.; Keiser, J.; Hartl, B. G.; Kraker, A. J.; Klohs, W. D.; Roberts, B. J.; Patmore, S.; Elliott, W. L.; Steinkampf, R.; Bradford, L. A.; Hallak, H.; Doherty, A. M. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J. Med. Chem. 1998, 41, 4365-4377.
25. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
26. Connolly, C. J. C.; Hamby, J. M.; Schroeder, M. C.; Barvian, M.; Lu, G. H.; Panek, R. L.; Amar, A.; Shen, C.; Kraker, A. J.; Fry, D. W.; Klohs, W. D.; Doherty, A. M. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 2415-2420.
27. de Laszlo, S. E.; Visco, D.; Agarwal, L.; Chang, L.; Chin, J.; Croft, G. ; Forsyth, A.; Fletcher, D.; Frantz, B.; Hacker, C.; Hanlon, W.; Harper, C.; Kostura, M.; Li, B.; Luell, S.; MacCoss, M.; Mantlo, N.; O'Neill, E. A.; Orevillo, C.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Sidler, K.; O'Keefe, S. J.; et al. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. 1998, 8, 2689-2694.
28. Dolle, R. E.; Dunn, J. A.; Bobko, M.; Singh, B.; Kuster, J. E.; Baizman, E.; Harris, A. L.; Sawutz, D. G.; Miller, D.; Wang, S.; et al. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 1994, 37, 2627-2629.
29. Dumas, J.; Hatoum-Mokdad, H.; Sibley, R.; Riedl, B.; Scott, W. J.; Monahan, M. K.; Lowinger, T. B.; Brennan, C.; Natero, R.; Turner, T.; Johnson, J. S.; Schoenleber, R.; Bhargava, A.; Wilhelm, S. M.; Housley, T. J.; Ranges, G. E.; Shrikhande, A. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2051-2054.
30. Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M. K.; Lee, W.; Lowinger, T. B.; Redman, A. M.; Johnson, J. S.; Kingery-Wood, J.; Scott, W. J.; Smith, R. A. ; Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J.; Bhargava, A.; Wilhelm, S. M.; Shrikhande, A. Discovery of a new class of p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2047-2050.
31. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. 1997, 5, 49-64.
32. Gibson, K. H.; Brundy, W.; Godfrey, A. A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumor activity of novel quinazolines. Bioorg. Med. Chem. Lett. 1997, 7, 2723-2728.
33. Hamby, J. M.; Connolly, C. J.; Schroeder, M. C.; Winters, R. T.; Showalter, H. D.; Panek, R. L.; Major, T. C.; Olsewski, B.; Ryan, M. J.; Dahring, T.; Lu, G. H.; Keiser, J.; Amar, A.; Shen, C.; Kraker, A. J.; Slintak, V.; Nelson, J. M.; Fry, D. W.; Bradford, L.; Hallak, H.; Doherty, A. M. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 1997, 40, 2296-2303.
34. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Stokes, E. S.; Ple, P. A.; Lohmann, J. J.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Curwen, J. O.; Kendrew, J.; Lambert-van der Brempt, C. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 1999, 42, 5369-5389.
35. Henry, J. R.; Rupert, K. C.; Dodd, J. H.; Turchi, I. J.; Wadsworth, S. A.; Cavender, D. E.; Fahmy, B.; Olini, G. C.; Davis, J. E.; Pellegrino-Gensey, J. L.; Schafer, P. H.; Siekierka, J. J. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor. J. Med. Chem. 1998, 41, 4196-4198.
36. Henry, J. R.; Rupert, K. C.; Dodd, J. H.; Turchi, I. J.; Wadsworth, S. A.; Cavender, D. E.; Schafer, P. H.; Siekierka, J. J. Potent inhibitors of the MAP kinase p38. Bioorg. Med. Chem. Lett. 1998, 8, 3335-3340.
37. Klutchko, S. R.; Hamby, J. M.; Boschelli, D. H.; Wu, Z.; Kraker, A. J.; Amar, A. M.; Hartl, B. G.; Shen, C.; Klohs, W. D.; Steinkampf, R. W.; Driscoll, D. L.; Nelson, J. M.; Elliott, W. L.; Roberts, B. J.; Stoner, C. L.; Vincent, P. W.; Dykes, D. J.; Panek, R. L.; Lu, G. H.; Major, T. C.; Dahring, T. K.; Hallak, H.; Bradford, L. A.; Showalter, H. D. H.; Doherty, A. M. 2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity. J. Med. Chem. 1998, 41, 3276-3292.
38. Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S. O.; Neill, E. A. O.; Keefe, S. J. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 1999, 42, 21180-2190.
39. Maguire, M. P.; Sheets, K. R.; McVety, K.; Spada, A. P.; Zilberstein, A. A new Series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J. Med. Chem. 1994, 37, 2129-2137.
40. Missbach, M.; Altmann, E.; Widler, L.; Susa, M.; Buchdunger, E.; Mett, H.; Meyer, T.; Green, J. Substituted 5,7-diphenylpyrrolo [2,3-d] pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg. Med. Chem. Lett. 2000, 10, 945-949.
41. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Persons, P. E.; Ly, C. Q.; Maguire, M. P.; Zulli, A. L.; Cheney, D. L.; Zilberstein, A.; Johnson, S. E.; Franks, C. F.; Mitchell, K. J. The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity. Bioorg. Med. Chem. Lett. 1997, 7, 421-424.
42. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Zulli, A. L.; Hsu, C.-Y. J.; Zilberstein, A.; Johnson, S. E.; Hook, L. E.; Jacoski, M. V. The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p561ck and EGF-R tyrosine kinase activity. Bioorg. Med. Chem. Lett. 1997, 7, 417-420.
43. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
44. Palmer, B. D.; Smaill, J. B.; Boyd, M.; Boschelli, D. H.; Doherty, A. M. ; Hamby, J. M.; Khatana, S. S.; Kramer, J. B.; Kraker, A. J.; Panek, R. L.; Lu, G. H.; Dahring, T. K.; Winters, R. T.; Showalter, H. D. H.; Denny, W. A. Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J. Med. Chem. 1998, 41, 5457-5465.
45. Palmer, B. D.; Kraker, A. J.; Hartl, B. G.; Panopoulos, A. D.; Panek, R. L.; Batley, B. L.; Lu, G. H.; Trumpp-Kallmeyer, S.; Showalter, H. D. H.; Denny, W. A. Structure-Activity Relationships for 5-Substituted 1-Phenylbenzimidazoles as Selective Inhibitors of the Platelet-Derived Growth Factor Receptor. J. Med. Chem. 1999, 42, 2373-2382.
46. Revesz, L.; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Zimmerlin, A. G. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 Map kinase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 1261-1264.
47. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenyl-methyl)amino]-and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
48. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 918-928.
49. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhou, H.; Fry, D. W.; McMichael, A.; Denny, W. A. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino] pyrido [d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 1823-1835.
50. Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Rubin, J. R.; Denny, W. A. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. J. Med. Chem. 1997, 46, 1820-1826.
51. Rewcastle, G. W.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Howard, C. T.; Nelson, J. M.; Roberts, B. J.; Vincent, P. W.; Showalter, H. D.; Winters, R. T.; Denny, W. A. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methyl-amino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J. Med. Chem. 1998, 41, 742-751.
52. Showalter, H. D.; Bridges, A. J.; Zhou, H.; Sercel, A. D.; McMichael, A. ; Fry, D. W. Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5-b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase. J. Med. Chem. 1999, 42, 5464-5474.
53. Sun, L.; Tran, N.; Liang, C.; Tang, F.; Rice, A.; Schreck, R.; Waltz, K. ; Shawver, L. K.; McMahon, G.; Tang, C. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem. 1999, 42, 5120-5130.
54. Sun, L.; Tran, N.; Liang, C.; Hubbard, S.; Tang, F.; Lipson, K.; Schreck, R.; Zhou, Y.; McMahon, G.; Tang, C. Identification of substituted 3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methy]ene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. J. Med. Chem. 2000, 43, 2655-2663.
55. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)-and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d] pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3780-3788.
56. Thompson, A. M.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Nelson, J. A.; Showalter, H. D.; Roberts, B. J.; Vincent, P. W.; Denny, W. A. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)aminolpyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1997, 40, 3915-3925.
57. Thompson, A. M.; Rewcastle, G. W.; Boushelle, S. L.; Hartl, B. G.; Kraker, A. J.; Lu, G. H.; Batley, B. L.; Panek, R. L.; Showalter, H. D. H.; Denny, W. A. Synthesis and Structure-Activity Relationships of 7-Substituted 3-(2,6-Dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as Selective Inhibitors of pp60c-src. J. Med. Chem. 2000, 43, 3134-3147.
58. Thompson, A. M.; Connolly, C. J.; Hamby, J. M.; Boushelle, S.; Hartl, B. G.; Amar, A. M.; Kraker, A. J.; Driscoll, D. L.; Steinkampf, R. W.; Patmore, S. J.; Vincent, P. W.; Roberts, B. J.; Elliott, W. L.; Klohs, W.; Leopold, W. R.; Showalter, H. D.; Denny, W. A. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and Related 2-Urea Derivatives Are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine Kinase. J. Med. Chem. 2000, 43, 4200-4211.
59. Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; N., L. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1996, 39, 2285-2292.
60. Traxler, P.; Green, J.; Mett, H.; Sequin, U.; P., F. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J. Med. Chem. 1999, 42, 1018-1026.
61. Wissner, A.; Berger, D. M.; Boschelli, D. H.; Floyd, M. B., Jr.; Greenberger, L. M.; Gruber, B. C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H. R.; Upeslacis, E.; Wang, Y. F.; Wu, B.; Ye, F. ; Zhang, N. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J. Med. Chem. 2000, 43, 3244-3256.
62. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B.; Traxler, P. (Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 1221-1226.
63. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B. Potent and selective inhibitors of the ABL-kinase: phenyl-aminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 1997, 7, 187-192.
64. Wang, J.; Szewczuk, Z.; Yue, S. Y.; Tsuda, Y.; Konishi, Y.; Purisima, E. O. Calculation of relative binding free energies and configurational entropies: a structural and thermodynamic analysis of the nature of nonpolar binding of thrombin inhibitors based on hirudin55-65. J. Mol. Biol. 1995, 253, 473-492.
65. Penel, S.; Doig, A. J. Rotamer strain energy in protein helices - quantification of a major force opposing protein folding. J. Mol. Biol. 2001, 305, 961-968.
66. Bohm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des. 1994, 8, 243-256.
67. D'Aquino, J. A.; Freire, E.; Amzel, L. M. Binding of small organic molecules to macromolecular targets: evaluation of conformational entropy changes. Proteins 2000, Suppl, 93-107.
68. Stouten, P. F. W.; Froemmel, C.; Nakamura, H.; Sander, C. An effective solvation term based on atomic occupancies for use in protein simulations. Mol. Simul. 1993, 10, 97-120.
69. Guner, O. F. Pharmacophore Perception, Development and Use in Drug Design.; International University Line: La Jolla, CA, 1999; p 537.
70. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277, 46265-46272.
71. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
72. Yamaguchi, H.; Hendrickson, W. A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996, 384, 484-489.
73. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289, 1938-1942.
74. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
75. Mohammadi, M.; Froum, S.; Hamby, J. M.; Schroeder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998, 17, 5896-5904.
76. Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 1997, 16, 5572-5581.